sarsassoci
coronaviru
sarscov
main
proteinas
key
enzym
viral
polyprotein
process
allow
structurebas
design
drug
direct
sarscov
main
proteinas
predict
bind
pocket
affin
exist
hiv
psychot
parasit
drug
lopinavir
ritonavir
niclosamid
promazin
show
sign
inhibit
replic
sarscov
result
suggest
drug
anoth
two
hiv
inhibitor
pnu
could
use
templat
design
sarscov
proteinas
inhibitor
elsevi
ltd
right
reserv
dock
problem
model
molecul
use
reemerg
sever
acut
respiratori
syndrom
sar
distinct
possibl
current
neither
antivir
therapi
vaccin
avail
viral
replicas
proteas
prefer
target
screen
design
antivir
compound
success
target
sever
viral
diseas
sarsassoci
coronaviru
sarscov
main
proteinas
mpro
pro
play
key
role
proteolyt
process
replicas
polyprotein
make
attract
target
develop
drug
new
diseas
recent
report
indic
proteinas
inhibitor
kaletra
mixtur
proteas
inhibitorslopinavir
ritonavir
approv
treat
hiv
show
sign
effect
sar
viru
particular
research
taiwan
discov
two
exist
medicin
signific
effect
inhibit
replic
sarscov
http
www
one
antiparasit
drug
niclosamid
anoth
antipsychot
drug
promazin
purpos
studi
analyz
whether
sarscov
main
proteinas
could
target
exist
drug
perform
silico
bind
studi
drug
use
recent
identifi
crystal
structur
mpro
provid
inform
antisar
inhibitor
design
atom
coordin
sarscov
main
proteinas
download
protein
data
bank
pdb
id
anoth
crystal
structur
sarscov
main
proteinas
also
avail
pdb
id
superposit
chain
chain
shown
figur
overlap
well
rmsd
chose
dock
studi
releas
earli
overal
structur
monom
sarscov
main
proteinas
compos
three
domain
domain
residu
domain
ii
residu
iii
residu
repres
green
pink
white
trace
figur
cleft
domain
ii
substratebind
site
except
four
drug
lopinavir
ritonavir
niclosamid
promazin
also
conduct
dock
studi
two
molecul
pnu
molecular
formula
close
niclosamid
promazin
respect
fig
inhibitor
revers
transcriptas
program
hex
employ
conduct
dock
ligand
sarscov
main
proteinas
basic
approach
parametr
function
encod
surfac
shape
electrostat
charg
potenti
distribut
surfac
shape
represent
use
novel
surfac
skin
model
protein
topolog
novel
soft
molecular
mechan
energi
minim
procedur
use
refin
candid
dock
solut
unlik
convent
fast
fourier
transform
fft
dock
approach
hex
use
spheric
polar
fourier
correl
acceler
dock
time
faster
fft
dock
algorithm
use
follow
paramet
set
correl
type
shape
three
probe
postprocess
mm
minim
steric
scan
maximum
final
search
maximum
other
default
set
structur
comparison
perform
lga
visual
structur
gener
proteinexplor
http
wwwproteinexplorerorg
figur
display
overal
structur
dock
four
drug
lopinavir
ritonavir
niclosamid
promazin
two
inhibitor
pnu
sarscov
main
proteinas
bind
pocket
compound
sarscov
main
proteas
shown
tabl
defin
residu
least
one
heavi
atom
hydrogen
distanc
less
heavi
atom
inhibitor
describ
chou
et
al
result
show
bind
pocket
six
compound
divid
three
class
residu
four
drugsinhibitor
lopinavir
niclosamid
promazin
pnu
residu
inhibitor
residu
drug
ritonavir
pocket
locat
domain
residu
domain
ii
residu
long
loop
region
residu
connect
domain
ii
sarscov
main
proteinas
thu
four
drug
two
inhibitor
studi
basic
bind
activ
site
sarscov
main
proteinas
cleft
domain
ii
estim
bind
affin
compound
inhibitori
constant
k
mole
calcul
equat
dg
free
energi
bind
kjmol
refer
final
dock
energi
r
ga
constant
jkmol
absolut
temperatur
k
jenwitheesuk
samudrala
result
indic
inhibitori
constant
six
compound
lopinavir
ritonavir
niclosamid
promazin
pnu
note
valu
low
exampl
inhibitori
constant
lopinavir
determin
jenwitheesuk
samudrala
reason
differ
dock
energi
valu
hex
program
pseudoenergi
design
give
reason
consist
unit
convent
energi
calcul
base
experiment
deriv
paramet
theoret
refer
valu
perform
dock
algorithm
thu
expect
valu
genuin
represent
inhibitori
constant
use
primarili
qualit
comparison
among
drugsinhibitor
studi
lower
k
greater
bind
affin
henc
hiv
drug
ritonavir
compound
bind
substrat
bind
site
sarscov
proteinas
highest
bind
affin
follow
hiv
inhibitor
pnu
antiparasit
drug
niclosamid
compound
lowest
bind
affin
moreov
inhibitori
constant
ritonavir
pnu
niclosamid
promazin
inhibitori
constant
lopinavir
respect
assum
valu
mol
lopinavir
inhibitori
constant
correct
inhibitori
constant
ritonavir
pnu
niclosamid
promazin
could
estim
mol
respect
close
view
interact
sarscov
main
proteinas
drugsinhibitor
exhibit
figur
result
show
half
lopinavir
left
outsid
catalyt
site
fig
ritonavir
thiazol
group
benzen
group
insert
specif
pocket
respect
anoth
benzen
side
chain
might
long
fit
substrat
bind
pocket
perfectli
fig
similar
situat
inhibitor
experiment
shown
bind
high
affin
sarscov
proteinas
http
wwwnaturecom
thu
efficaci
lopinavirritonavir
could
poor
inde
consist
predict
experiment
observ
data
indic
lopinavir
ritonavir
individu
weak
vitro
activ
sarscov
howev
addit
lopinavirritonavir
ribavirin
corticosteroid
treatment
regimen
appear
reduc
incub
mortal
rate
especi
administ
earli
similarli
half
niclosamid
promazin
left
outsid
activ
site
fig
obvious
propan
side
chain
promazin
long
pnu
inhibitor
seem
basic
fit
activ
cleft
except
dihydrofuran
side
chain
littl
bit
long
fig
final
inhibitor
bind
posit
slightli
away
activ
centr
fig
neopentan
methylfuran
side
chain
littl
long
make
unabl
insert
activ
pocket
properli
inde
compound
lowest
bind
affin
mention
taken
togeth
studi
illustr
exist
drugsinhibitor
may
use
start
point
discoveri
ration
design
antisar
proteinas
drug
